Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimization and characterization of tRNA-shRNA expression constructs.

Lisa J Scherer1, Richard Frank, John J Rossi

  • 1Department of Molecular Biology Beckman Research Institute of the City of Hope, 1450 E. Duarte Road, Duarte, California 91010, USA.

Nucleic Acids Research
|April 12, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Revisiting long-standing biological questions through evolving technologies.

Bioscience trends·2026
Same author

RNA activation as a precision dosing modality: MTL-CEBPA for controlled enzyme elevation in MPS I-H.

Frontiers in medicine·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

C/EBPβ stabilizes oxidative stress in triple-negative breast cancer cells, driving taxane resistance and immune evasion.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

ASOs reduce SARS-CoV-2 viral titers in Syrian golden hamsters.

Molecular therapy. Nucleic acids·2025
Same author

A hypoxia-responsive tRNA-derived small RNA confers renal protection through RNA autophagy.

Science (New York, N.Y.)·2025
Same journal

Neurochondrin promotes U5 snRNP maturation by regulating AAR2 release from PRPF8.

Nucleic acids research·2026
Same journal

Elongationless start-stop elements are stress-resilient translation gates that are more repressive than uTranslons.

Nucleic acids research·2026
Same journal

Evolution of the ribosomal exit tunnel through the eyes of the nascent chain.

Nucleic acids research·2026
Same journal

Enhancing the performance and interpretability of epigenetic clocks.

Nucleic acids research·2026
Same journal

FABIAN-variant 2026: improved prediction of the effects of DNA variants on transcription factor binding.

Nucleic acids research·2026
Same journal

Structural and biochemical characterization of Grimontia hollisae thermostable direct hemolysin with DNA reveals first Vibrio hemolysin with nuclease activity.

Nucleic acids research·2026
See all related articles

Researchers developed novel tRNA-shRNA expression systems for RNA interference (RNAi). These systems offer an alternative to U6 and H1 promoters, potentially improving HIV treatments by reducing viral resistance.

Area of Science:

  • Molecular Biology
  • Gene Silencing
  • RNA Interference (RNAi)

Background:

  • PolIII-based transcription systems effectively express short hairpin RNAs (shRNAs) for RNAi in mammalian cells.
  • U6 and H1 promoters are commonly used for shRNA expression due to ease of manipulation.
  • Multiplexing siRNAs against multiple targets is a strategy for HIV treatment to prevent viral resistance.

Purpose of the Study:

  • To develop alternative small PolIII promoters for shRNA expression beyond U6 and H1.
  • To assess the efficacy and strand selectivity of tRNA(Lys3)-shRNA chimeric expression cassettes.
  • To establish guidelines for expressing effective tRNA-shRNAs with graded response and minimized toxicity.

Main Methods:

  • Construction of tRNA(Lys3)-shRNA chimeric expression cassettes.

Related Experiment Videos

  • Evaluation of siRNA production and RNAi efficacy compared to U6-expressed shRNAs.
  • Analysis of siRNA strand selectivity and processing by endogenous 3' tRNAse.

    • Main Results:

    • tRNA(Lys3)-shRNA cassettes produced siRNAs with efficacy and strand selectivity comparable to U6-expressed shRNAs.
    • The activity of tRNA-shRNAs was consistent with processing by endogenous 3' tRNAse.
    • Guidelines were suggested for expressing effective tRNA-shRNAs with potential for graded response.

    Conclusions:

    • tRNA(Lys3)-shRNA chimeric expression cassettes represent a viable alternative to U6 and H1 promoters for RNAi.
    • These novel cassettes offer a promising strategy for developing improved RNAi-based therapeutics, including for HIV.
    • The findings provide a foundation for optimizing tRNA-shRNA expression to enhance therapeutic outcomes and reduce off-target effects.